Astria Therapeutics, Inc. stock is down -7.41% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 November’s closed higher than October. 100% of analysts rate it a buy.
Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.